Evaxion Biotech A/S
EVAXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 9, 2026 |
| Lake Street | maintain | Buy | Mar 9, 2026 |
| Lake Street | maintain | Buy | Oct 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 20, 2025 |
| Lake Street | maintain | Buy | Feb 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2024 |
| Ladenburg Thalmann | upgrade | Neutral →Buy | Apr 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2024 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Dec 21, 2023 |
| Lake Street | maintain | Buy | Mar 30, 2023 |
| Oppenheimer | maintain | Outperform | Nov 16, 2022 |
| Oppenheimer | maintain | Outperform | Mar 2, 2021 |
Earnings History
Next report: Nov 19, 2026 · EPS est. $-0.01| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.01 | $-0.01 | — | $6.7M |
| May 26, 2026 | $-0.01 | $-0.01 | — | $9.2M |
| Mar 5, 2026 | $-0.02 | $-0.24 | — | $7.5M |
| Oct 30, 2025 | $0.01 | $-0.01 | $7.5M | $3.8M |
| Aug 14, 2025 | $-0.76 | $-0.50 | $37.0K | $8.0M |
| May 27, 2025 | $-0.29 | $-0.65 | — | $60.0K |
| Mar 26, 2025 | $-3.40 | $-0.26 | $122.0K | $1.7M |
| Oct 31, 2024 | $-0.20 | $-0.31 | $3.0M | $123.3K |
News
COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk. Valuation and Earnings This table compares Evaxion A/S
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026 COPENHAGEN, Denmark, November 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for E…
New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, …
COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology™ as best digital health solution. It is the first time the prestigious international award has been won by a Danish company.
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and traded as low as $2.95. Evaxion A/S shares last traded at $3.08, with a volume of 219,538 shares. Analyst Ratings Changes Separately, Weiss
COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Profitability This table compares Evaxion A/S and Nektar
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatments Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026 …
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM.